Bumetanide- loop diuretic of the sulfamyl category to treat heart failure.

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in people in whom high doses of furosemide are ineffective.

Bumetanide- loop diuretic of the sulfamyl category to treat heart failure.

3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; Bumex; Fordiuran

3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid

Bumetanide induces diuresis by inhibiting reabsorption of water and electrolytes (sodium and chloride) in the ascending loop of Henle and proximal renal tubule.

Dose should be depends on patient’s condition.

Indicated for the treatment of hypertension, oedema and in pulmonary Oedema. 

Muscle cramps, dizziness, hypotension, headache, nausea, impaired hearing, pruritus, ECG changes, musculoskeletal pain, rash, chest discomfort, renal failure, premature ejaculation, hypokalaemia, thrombocytopenia, hypomagnesaemia, hyponatraemia, hyperglycaemia, hyperuricaemia, hypocalcaemia.

• Reduced diuretic and natriuretic actions by probenecid.
• Avoid concurrent usage with ototoxic drugs such as aminoglycoides and nephrotoxic drugs.
• Indomethacin blunts action of bumetanide
• Concurrent usage with antihypertensives may increase risk of orthostatic hypotension.
• Reduced lithium excretion via kidneys.

Hypersensitivity, progressive renal failure and anuria, hepatic coma, severe electrolyte depletion.

Store at 15-30 degree centigrade.

Molecular weight

364.416

Molecular formula

C17H20N2O5S

CAS number

28395-03-1

Precautions

• Regular monitoring of serum electrolytes (especially calcium, potassium, magnesium); in case of hypokalemia, potassium supplements/potassium-sparing diuretics added.
• Pregnancy, lactation;
• Monitor blood-glucose, creatinine levels as well as blood counts. BUN, Sulfonamide allergy.
• CHF patients on digitalis, K losing nephropathy, hepatic cirrhosis and ascitis, diarrhoeal states.